By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel is divided on Bristol Myers Squibb (BMY). While some argue that the growth portfolio could offset the 2028 patent cliffs of Eliquis and Opdivo, others caution that the timeline for acquired assets like Karuna's schizophrenia drug may not provide enough buffer, and the company's R&D productivity is a systemic risk.
Risk: The mismatch between the launch timelines of acquired assets and the end of Eliquis and Opdivo's exclusivity, as well as BMY’s R&D productivity.
Opportunity: The optionality embedded in recent M&A, particularly the breakthrough potential in neuroscience from acquisitions like Karuna Therapeutics.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Bristol Myers Squibb faces a daunting patent cliff.
The company has a promising growth portfolio, but it may not be able to fully offset losses from older drugs.
Income investors and patient investors who aren't risk-averse could still find Bristol Myers Squibb stock attractive.
Bristol Myers Squibb's (NYSE: BMY) shares are rebounding after sinking roughly 11%. However, the big pharma stock remains below the early March year-to-date peak. With a forward price-to-earnings multiple of only 9.4, Bristol Myers Squibb may seem to be an attractive pick for value investors.
But numbers don't always tell the full story. Looking to buy Bristol Myers Squibb on the dip? There's something you need to know first.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Some stocks are cheap for a season. Others are cheap for a reason. Bristol Myers Squibb definitely falls into the latter category right now. The drugmaker faces multiple risks that investors shouldn't ignore.
A daunting patent cliff tops the list. Sales for blood cancer drug Revlimid are already declining sharply in the wake of generic competition. Bristol Myers Squibb's two top-selling products, the blood thinner Eliquis and the cancer immunotherapy Opdivo, lose U.S. patent exclusivity in 2028.
Don't rate Bristol Myers Squibb as a great value stock solely because of its low forward earnings multiple. Because of the company's patent cliff, any valuation metrics based on 2026 or 2027 earnings are practically useless.
Sure, Bristol Myers Squibb has completed multiple acquisitions to boost its growth prospects. The company bought Mirati Therapeutics, Karuna Therapeutics, and RayzeBio in 2023. It acquired 2seventy bio and Orbital Therapeutics last year. While acquisitions offer potential, they also entail integration and clinical risks.
Bristol Myers Squibb executives focus heavily on the drugmaker's growth portfolio rather than its legacy drugs. They emphasized in the 2026 first-quarter earnings update that the growth portfolio accounted for the majority of total revenue. That's true, but the legacy portfolio still makes up roughly 46% of revenue. With total revenue increasing by only 1% on a constant-currency basis, there's a real possibility that the growth drugs won't be able to offset losses from the older blockbusters.
Do these risks mean that Bristol Myers Squibb is a stock to avoid? Not necessarily. Whether or not buying the stock on the dip makes sense depends on your investing style and risk tolerance.
Risk-averse investors will probably be better off finding other stocks to buy. It's a similar story for investors with short investing time horizons. Bristol Myers Squibb's fortunes won't improve dramatically over the next couple of years.
However, patient investors who aren't afraid to take on risk could like Bristol Myers Squibb's long-term prospects. Income investors will also probably find the company's 4.2% dividend yield enticing.
Bristol Myers Squibb could be a good stock to buy on the dip, but only for some investors.
Before you buy stock in Bristol Myers Squibb, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $477,813! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,320,088!
Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 24, 2026. *
Keith Speights has positions in Bristol Myers Squibb. The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"BMY's valuation ignores the 2028 patent losses on two top products that still anchor nearly half of revenue."
The article correctly flags BMY's patent cliff but underplays how little time the growth portfolio has to scale before Eliquis and Opdivo lose U.S. exclusivity in 2028. Legacy products still generate 46% of sales while constant-currency revenue rose only 1% last quarter. Acquisitions such as Karuna and RayzeBio add binary clinical and integration risk rather than near-term cash flow. At 9.4x forward earnings the multiple looks cheap only if one assumes the 2026-27 earnings base survives; history shows pharma multiples compress further once visibility on post-patent revenue declines. Income investors chasing the 4.2% yield may face cuts if cash flows weaken faster than expected.
The new assets could deliver earlier-than-modeled approvals or outsized uptake, allowing the growth portfolio to more than replace lost legacy revenue by 2029 and justify a re-rating.
"BMY is not a value trap or a steal—it's a binary bet on whether $8B+ in recent acquisitions generate enough blockbuster revenue by 2030 to offset the patent cliff, and the article doesn't quantify what 'enough' actually means."
The article frames BMY as a value trap, and that's partially right—but it conflates near-term pain with long-term value destruction. Yes, Eliquis and Opdivo face 2028 patent cliffs. Yes, legacy drugs are 46% of revenue. But the article glosses over two things: (1) BMY's growth portfolio now drives majority revenue and is still early-stage (Karuna, RayzeBio assets haven't peaked); (2) a 9.4x forward P/E on a pharma company with 4.2% yield and $10B+ annual free cash flow is genuinely cheap IF the growth portfolio compounds at mid-teens rates post-2028. The real question isn't whether the cliff exists—it does—but whether management's M&A thesis actually works. That's a 3-5 year bet, not a 2-year one.
If BMY's growth portfolio underperforms clinical expectations (common in biotech M&A) or if integration costs balloon, the company could face a revenue cliff in 2029-2030 that no valuation multiple can justify. The 1% constant-currency revenue growth is a red flag—it suggests the growth drugs aren't yet compensating.
"BMY's current valuation reflects a 'worst-case' terminal decline scenario, failing to account for the potential upside of its recent neuroscience-focused M&A pipeline."
The article correctly highlights the 'patent cliff' as the primary headwind for BMY, but it misses the critical nuance of the capital allocation strategy. Trading at ~9.4x forward P/E, BMY is priced for terminal decline, yet the market is ignoring the optionality embedded in their recent M&A spree. Acquisitions like Karuna Therapeutics provide genuine breakthrough potential in neuroscience, which isn't yet reflected in the valuation. While legacy revenue is indeed eroding, the market is over-discounting the transition period. If even one of the late-stage pipeline assets hits a major commercial milestone, the current valuation floor provides a significant margin of safety for long-term income-oriented investors.
The thesis assumes successful integration of high-priced acquisitions, ignoring the historical reality that big pharma often overpays for R&D that fails to reach the scale necessary to replace multi-billion dollar blockbusters like Eliquis.
"BMY's cheap forward multiple hides a structural earnings risk from the patent cliff that won't be offset unless the growth portfolio delivers material near-term revenue growth."
Article flags a patent cliff for BMY as the main risk and notes a still-growing, yet uncertain, pipeline. The kicker is that Eliquis and Opdivo patent protection ends in 2028, and Revlimid faces ongoing generic erosion; even if the growth portfolio expands, the legacy base could drag earnings for years. The piece suggests cheap valuation (forward P/E around 9.4) but that multiple may compress further if 2026–27 earnings prove unsustainable and pipeline milestones lag. Acquisitions add risk (integration, regulatory reviews) and near-term cash flow could stay under pressure without offsetting launches.
If BMY executes the growth portfolio and secures pipeline milestones by 2026–2028, the stock could re-rate despite the 2028 patent cliff, and the 4% dividend remains appealing.
"Launch timelines for Karuna and similar assets create a dangerous gap before the 2028 patent cliff."
Claude's optimism on the growth portfolio compounding post-2028 overlooks the launch timelines for acquired assets. Karuna's schizophrenia drug faces FDA decision in late 2024 with commercial ramp likely extending into 2027-2029, leaving little buffer before Eliquis and Opdivo exclusivity ends. This mismatch increases the probability that 2026-27 earnings erode faster than modeled, pressuring both the multiple and the dividend. Historical pharma M&A shows such delays are common, amplifying integration risks already noted.
"Launch timing matters less than peak sales potential—Karuna needs to hit $3B+ to justify the acquisition thesis, and the panel hasn't stress-tested that assumption."
Grok's timeline critique is sharp, but misses that Karuna's schizophrenia asset (KarXT) already has a complete Phase 3 dataset—FDA decision is imminent, not speculative. Commercial ramp into 2027-29 is realistic, but that overlaps Eliquis/Opdivo cliffs by design, not accident. The real risk: whether Karuna's peak sales ($2-3B consensus) materially moves BMY's needle post-2028. If it doesn't, the M&A thesis collapses regardless of launch timing. Nobody's quantified the revenue replacement math.
"Individual asset successes like KarXT are mathematically insufficient to replace the impending revenue loss from Eliquis and Opdivo."
Claude, your focus on KarXT misses the real systemic risk: BMY’s R&D productivity. Even if KarXT hits $3B, that’s a fraction of the $10B+ revenue hole created by the 2028 cliffs. We are debating individual assets while ignoring the company’s structural inability to generate organic innovation. Relying on M&A to bridge a massive patent gap isn't a strategy; it's a desperate attempt to buy time that inevitably leads to margin dilution and balance sheet strain.
"Margin compression from SG&A growth and payer pricing pressure could erode FCF ahead of 2028, challenging valuation even with a few asset peaks."
Gemini, you bank on one big hit from Karuna/RayzeBio, but you ignore the margin erosion risk from commercializing a broader growth portfolio. Even with a few $2-3B peaks, SG&A ramps, payer discounts, and potential milestone-triggered earnouts can compress FCF ahead of 2028. A high hurdle to offset the cliff is not just revenue replacement; it’s margin compression risk that could re-rate the stock downward before any milestone hits.
The panel is divided on Bristol Myers Squibb (BMY). While some argue that the growth portfolio could offset the 2028 patent cliffs of Eliquis and Opdivo, others caution that the timeline for acquired assets like Karuna's schizophrenia drug may not provide enough buffer, and the company's R&D productivity is a systemic risk.
The optionality embedded in recent M&A, particularly the breakthrough potential in neuroscience from acquisitions like Karuna Therapeutics.
The mismatch between the launch timelines of acquired assets and the end of Eliquis and Opdivo's exclusivity, as well as BMY’s R&D productivity.